Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
INOVOLINE
Phase NA Completed
101 enrolled
Study of ESG401 in Adults With Solid Tumors
Phase 1/2 Completed
156 enrolled
EARN
Phase NA Completed
33 enrolled
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
KEYVIBE-005
Phase 2 Completed
613 enrolled
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Phase 1/2 Completed
84 enrolled
Genomic Testing and Resulting Medical Decisions
Completed
1,500 enrolled
PREFER
Completed
1,429 enrolled
Safety Study of MGAH22 in HER2-positive Carcinomas
Phase 1 Completed
66 enrolled
K-DETEK
Completed
9,057 enrolled
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Phase 1 Completed
13 enrolled 11 charts
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Phase 1 Completed
112 enrolled
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Phase NA Completed
128 enrolled 24 charts
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
Phase 1/2 Completed
71 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Phase 1 Completed
279 enrolled
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Phase 1 Completed
29 enrolled
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein
Phase 1 Completed
14 enrolled
DUET-3
Phase 1 Completed
198 enrolled
GS3
Completed
15,958 enrolled
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Phase 1/2 Completed
203 enrolled
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
Phase 1 Completed
63 enrolled
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
Phase 1 Completed
23 enrolled
CAPABLE-IT
Phase NA Completed
56 enrolled
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Phase 1 Completed
106 enrolled
Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
Completed
169 enrolled
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Phase 1/2 Completed
49 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
DUET-4
Phase 1 Completed
78 enrolled
PIVOT-02
Phase 1/2 Completed
557 enrolled 22 charts
Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With HerceptinĀ® in Healthy Male Volunteers
Phase 1 Completed
89 enrolled
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Phase 1 Completed
15 enrolled
DUET-2
Phase 1 Completed
150 enrolled
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
Phase 1 Completed
12 enrolled 15 charts
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Completed
722 enrolled
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
Phase 1 Completed
25 enrolled 17 charts
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
52 enrolled 25 charts
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Completed
5,133 enrolled
DETECT
Completed
458 enrolled
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
139 enrolled
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
Phase 1 Completed
53 enrolled
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Phase 1/2 Completed
444 enrolled 19 charts
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Phase 1 Completed
40 enrolled
HITM-SURE
Phase 1 Completed
5 enrolled
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Phase 1 Completed
54 enrolled
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled